Detection of EGFR gene mutations in non-small cell lung cancer: Lessons from a single-institution routine analysis of 1,403 tumor samples

摘要: Activating mutations of the epidermal growth factor receptor (EGFR) in lung tumors are associated with a dramatic response to tyrosine kinase inhibitors. Therefore, routine analysis pathological specimens is mandatory clinical practice. We have prospectively tested from Caucasian tumor patients between January 2010 and June 2012. DNA was extracted formalin-fixed paraffin-embedded tissues following macrodissection. The p.L858R substitution assessed by allele-specific PCR exon 19 deletions fragment analysis. Using robust process patient sampling screening methods, we analyzed samples 1,403 patients. EGFR status could be successfully determined for 1,322 were detected 179 (13.5%) patients, female adenocarcinoma histology predominance. Mutated significantly older than non-mutated Similar mutation rates obtained primary metastases, surgical resection, bronchial biopsies, CT-guided needle biopsies transbronchial aspiration. sensitivity our assays allowed us detect poor (<10%) cells. Finally, rate much higher expressing TTF-1 antigen (145/820; 17.7%) negative (3/218; 1.4%). results through more 1,300 indicated that all types specimen can without any significant bias. immunostaining may used predict status.